



Company Announcement Office Australian Securities Exchange Level 4, 20 Bridge Street Sydney NSW 2000

16 October 2018

COMPLETION OF PLACEMENT

Diatreme Resources Limited (ASX: DRX) ("**Diatreme**" or "**Company**") is pleased to announce it has completed the placement program, as announced to market on 5 October 2018, to professional and sophisticated investors ("**Placees**").

Following completion of the placement the Company has now received total funds (before costs) of \$2,137,523 ("Placement") through the issue of 106,876,154 fully paid ordinary shares at \$0.020 per share ("Placement Shares"). The shares have a free attaching option issued on a 1 option for every two shares basis (1:2), equating to 53,438,077 free-attaching options (Placement Options) to be issued. The Placement Options have an exercise price of \$0.03 per option and expire 14 months from date of issue.

The Company has also agreed to some of the costs associated with the placement program to be converted to shares and options. Accordingly, a further 1,818,500 Placement Shares and 7,409,250 Placement Options will be issued by the Company

Under the terms of the placement agreement, the Placees' subscriptions for the Placement Options were subject to, and conditional upon, shareholder approval being obtained within 120 days of the Placement Shares being issued (**Approval Condition**).

The Company has now determined that it has sufficient placement capacity under listing rule LR7.1 to issue the Placement Options without the need for the Approval Condition. Accordingly Diatreme now waives the Approval Condition and will today issue the Placement Options and apply to ASX for their quotation.

The Directors wish to thank again the incoming investors and welcome them to the Company.

The Appendix 3B relating to this placement program is attached.

Yours faithfully Tuan Do Company Secretary

+617 3397 2222

AUSTRALIAN SANDS. UNIVERSAL DEMAND.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

DIATREME RESOURCES LIMITED

ARN

33 061 267 061

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- (a) Fully paid ordinary shares
- (b) Listed Options
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- (a) 108,694,654 (b) 60,847,327
- Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)
- (a) Fully paid ordinary shares
- (b) Listed Options, exercise price of \$0.03 per option and expire 14 months from date of issue

⁺ See chapter 19 for defined terms.

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- (a) Yes the shares issued rank equally with existing fully paid ordinary shares
- (b) Shares issued on the exercise of the Listed Options will rank equally with existing fully paid ordinary shares

- 5 Issue price or consideration
- (a) \$0.020 per share
- (b) Free Option
- 6 Purpose of the issue
 (If issued as consideration for the acquisition of assets, clearly identify those assets)

Placement to professional and sophisticated investors

6a Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b-6h in relation to the $^+securities$ the subject of this Appendix 3B, and comply with section 6i

30/05/18

Yes

6b The date the security holder resolution under rule 7.1A was passed

6c Number of *securities issued without security holder approval under rule 7.1

101,017,550

6d Number of *securities issued with security holder approval under rule 7.1A

68,524,431

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A		
6f	Number of *securities issued under an exception in rule 7.2	N/A		
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	VWAP date 15 day VW 75% VWAI Issue price		2018
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1: Rule 7.1A: Total:	Nil 38,906,528 38,906,528	
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	16 October	- 2018	
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	Number 1,243,133,	134	+Class Fully paid ordinary shares (DRX)

⁺ See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	†Class
7,000,000	Unlisted options exercisable at 10 cents each expiring 30 April 2019
60,847,327	Listed options exercisable at 3 cents each expiring 14 months from date of issue (16 Dec 2019)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
		22/1
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A

⁺ See chapter 19 for defined terms.

33	⁺ Issue	date	N/A
		uotation of securitie	
34	Type of tick of	of *securities ne)	
(a)	\checkmark	⁺ Securities described in Part 1	
(b)			of the escrowed period, partly paid securities that become fully paid, employed ends, securities issued on expiry or conversion of convertible securities
Entit	ies tha	t have ticked box 34(a)	
Addi	tional s	ecurities forming a new cla	ss of securities (Not applicable)
Tick to docum		e you are providing the informat	ion or
35	\checkmark		securities, the names of the 20 largest holders of the number and percentage of additional *securities held by
36	√		y securities, a distribution schedule of the additiona ber of holders in the categories
37		A copy of any trust deed for the	ne additional *securities

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number	⁺ Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at the
 time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 16 October 2018

(Company Secretary)

Print name: Tuan Do

== == == == ==

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1 -

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities.	20,000,000 (App 3B - 13/4/18) 25,000,000 (App 3B - 5/4/18) 5,000,000 (App 3B - 1/3/18) 20,000,000 (App 3B - 13/2/18) 10,000,000 (App 3B - 30/1/18) 15,000,000 (App 3B - 23/11/17) 28,076,912 (App 3B - 8/11/17)	
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary 	24,500,000 (Approved at 5 April 2018 EGM)	
securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	25,000,000	
"A"	1,074,309,591	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	161,146,439	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
 Insert number of ⁺equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 	13,888,889 (App 3B – 16/5/18) 11,375,000 (App 3B – 1/8/18) 34,865,000 (App 3B – 2/10/18)	
 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 	101,017,550 (Subject of this App 3B)	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	161,146,439	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15 Note: number must be same as shown in Step 2	161,146,439	
Subtract "C" Note: number must be same as shown in Step 3	161,146,439	
<i>Total</i> ["A" x 0.15] – "C"	Nil [Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2 -

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
"A" Note: number must be same as shown in Step 1 of Part 1	1,074,309,591		
Step 2: Calculate 10% of "A"			
"D"	0.10 Note: this value cannot be changed		
Multiply "A" by 0.10	107,430,959		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
 Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	68,524,431 (Subject of this App 3B)		
"E"	68,524,431		

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	107,430,959	
Note: number must be same as shown in Step 2		
Subtract "E"	68,524,431	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	38,906,528	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.